FDA actions in brief
FDA approved the etonogestrel 68-mg implant (Implanon, Organon), a single-rod implantable device that prevents pregnancy for up to 3 years.
FDA approved the etonogestrel 68-mg implant (Implanon, Organon), a single-rod implantable device that prevents pregnancy for up to 3 years.
FDA approved rivastigmine (Exelon, Novartis) as the first treatment for mild-to-moderate dementia associated with Parkinson disease.
Bevacizumab (Avastin, Genentech) was approved in combination with intravenous 5-fluorouracil (5-FU)-based chemotherapy for the treatment of second-line metastatic colorectal cancer. The agent had been previously approved for first-line treatment of metastatic colorectal cancer in combination with IV 5-FU-based chemotherapy.
A topical anesthetic peel, packaged as a lidocaine 7%/tetracaine 7% cream formulation (Zars Pharma), was approved to be used prior to various superficial dermatologic procedures.
FDA Accepts NDA for Zoliflodacin, Potentially First Gonorrhea Antibiotic in Decades
June 13th 2025The FDA has accepted a New Drug Application for zoliflodacin, a first-in-class oral antibiotic for treating uncomplicated gonorrhea, offering a potential new option amid rising antibiotic resistance.
Read More
